471270-58-3Relevant academic research and scientific papers
Novel platinum(II) and palladium(II) complexes with cyclin-dependent kinase inhibitors: Synthesis, characterization and antitumour activity
Szucova, Lucie,Travnicek, Zdenek,Zatloukal, Marek,Popa, Igor
, p. 479 - 491 (2006)
The Pt(II) and Pd(II) complexes of the types cis-[Pt(L1) 2Cl2]?H2O (1), cis-[Pt(L2) 2Cl2]?3H2O (2), trans-[Pd(L 1)2Cl2]?H2O
Synthesis and biological activity of olomoucine II.
Krystof, Vladimir,Lenobel, Rene,Havlicek, Libor,Kuzma, Marek,Strnad, Miroslav
, p. 3283 - 3286 (2002)
Based on our previous experiences with synthesis of purines, novel 2,6,9-trisubstituted purine derivatives were prepared and assayed for the ability to inhibit CDK1/cyclin B kinase. One of newly synthesized compounds designated as olomoucine II, 6-[(2-hydroxybenzyl)amino]-2-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine, displays 10 times higher inhibitory activity than roscovitine, potent and specific CDK1 inhibitor. Olomoucine II in vitro cytotoxic activity exceeds purvalanol A, the most potent CDK inhibitor, as it kills the CEM cells with IC(50) value of 3.0 microM.
The first iron(III) complexes with cyclin-dependent kinase inhibitors: Magnetic, spectroscopic (IR, ES+ MS, NMR, 57Fe M?ssbauer), theoretical, and biological activity studies
Trávní?ek, Zdeněk,Popa, Igor,?ajan, Michal,Zbo?il, Radek,Kry?tof, Vladimír,Mikulík, Ji?í
scheme or table, p. 405 - 417 (2011/12/22)
The first FeIII complexes 1-6 with cyclin-dependent kinase (CDK) inhibitors of the type [Fe(Ln)Cl3]·nH2O (n=0 for 1, 1 for 2, 2 for 3-6; L1-L6=C2- and phenyl-substituted CDK inhibitors derived from 6-benzylamino-9-isopropylpurine), have been synthesized and characterized by elemental analysis, IR, 57Fe Mo?ssbauer, 1H and 13C NMR, and ES+ mass spectroscopies, conductivity and magnetic susceptibility measurements, and thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC). The study revealed that the compounds are mononuclear, tetrahedral high-spin (S=5/2) FeIII complexes with an admixture of an S=3/2 spin state originating probably from five-coordinated FeIII ions either connecting with a bidentate coordination mode of the CDK inhibitor ligand or relating to the possibility that one crystal water molecule enters the coordination sphere of the central atom in a portion of molecules of the appropriate complex. Nearly spin-only value of the effective magnetic moment (5.82μeff/μB) was determined for compound 1 due to absence of crystal water molecule(s) in the structure of the complex. Based on NMR data and DFT calculations, we assume that the appropriate organic ligand is coordinated to the FeIII ion through the N7 atom of a purine moiety. The cytotoxicity of the complexes was tested in vitro against selected human cancer cell lines (G-361, HOS, K-562 and MCF-7) along with the ability to inhibit the CDK2/cyclinE kinase. The best cytotoxicity (IC50: 4-23μM) and inhibition activity (IC50: 0.02-0.09μM) results have been achieved in the case of complexes 2-4, and complexes 3, 4 and 6, respectively. In addition, the X-ray structure of 2-chloro-6-benzylamino-9-isopropylpurine, i.e. a precursor for the preparation of L1, L4 and L5, is also described.
